1. Home
  2. NYC vs GRDX Comparison

NYC vs GRDX Comparison

Compare NYC & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Strategic Investment Co.

NYC

American Strategic Investment Co.

HOLD

Current Price

$8.52

Market Cap

24.8M

Sector

Finance

ML Signal

HOLD

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

N/A

Current Price

$6.27

Market Cap

28.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NYC
GRDX
Founded
2013
N/A
Country
United States
United Kingdom
Employees
N/A
2
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.8M
28.6M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
NYC
GRDX
Price
$8.52
$6.27
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
28.1K
157.7K
Earning Date
04-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
85.28
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$56.73
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.03
$1.87
52 Week High
$16.30
$6.93

Technical Indicators

Market Signals
Indicator
NYC
GRDX
Relative Strength Index (RSI) 51.87 72.74
Support Level $7.87 $2.16
Resistance Level $10.29 $6.93
Average True Range (ATR) 0.74 0.65
MACD -0.10 0.09
Stochastic Oscillator 17.56 81.29

Price Performance

Historical Comparison
NYC
GRDX

About NYC American Strategic Investment Co.

American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: